A I Chebli, Z Chelighem, Y Zebbiche, S Abdennour, A Amziane, R Djidjik
{"title":"Factors Associated with Therapeutic Non-Adherence in Asthmatic Patients: A Multicenter Study in Algeria.","authors":"A I Chebli, Z Chelighem, Y Zebbiche, S Abdennour, A Amziane, R Djidjik","doi":"10.1016/j.pharma.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.10.010","url":null,"abstract":"<p><strong>Introduction: </strong>Effective medication adherence, is a real global challenge that emerges as a pivotal factor influencing asthma control, exacerbation frequency, hospitalization rates and ultimately, mortality, morbidity and health care costs. In light of this, our study aimed to assess therapeutic adherence levels among asthmatic patients and identify factors contributing to non-adherence.</p><p><strong>Methods: </strong>We conducted a descriptive, cross-sectional multicenter study, among asthmatic patients receiving outpatient or inpatient care across seven asthma centers located in two Algerian cities: Algiers (University Hospital Center of Benimessous, University Hospital Center of Bab el oued, EPSP of Zeralda, EPSP of Beraki and EPSP of Rouiba) and Constantine (Constantine University Hospital Center (CHU), EPSP of Constantine), between July and December 2023. We evaluated therapeutic adherence using the Morisky 8-item questionnaire, while a 12-item questionnaire assessed patients' knowledge levels. Logistic regression analysis enabled us to identify factors associated with non-adherence.</p><p><strong>Results: </strong>Our study, involved 390 patients, with a median age of 34 years and a sex ratio of 1.5. Notably, 38.2% of asthmatic patients exhibited poor adherence to treatment. Multivariate analysis revealed several factors potentially linked to non-adherence, including, age, place of residence, employment status, access to social insurance, treatment type and complexity, auto-medication, occurrence of adverse effects, limited level of education and inadequate knowledge about asthma management. Furthermore, there was a significant correlation between non-adherence and a higher rate of asthma exacerbations, with a reported occurrence of 68%.</p><p><strong>Conclusion: </strong>our findings emphasize concerning levels of therapeutic adherence, given its impact on disease control and the quality of life of asthmatic patients. This underscores the importance of implementing a therapeutic education program aimed at improving treatment adherence by addressing the factors identified as barriers in clinical patient management.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Automated dispensing cabinet: an evaluation of professional practices that says much more than what the authors write.]","authors":"B Charpiat","doi":"10.1016/j.pharma.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.10.011","url":null,"abstract":"","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advanced stability-indicating RP-HPLC method for the quantification of Lurasidone Hydrochloride in bulk and PLGA based in-situ implant formulation.","authors":"Bankar Anup Ramprasad, Sundeep Chaurasia, Indu Singh","doi":"10.1016/j.pharma.2024.10.008","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.10.008","url":null,"abstract":"<p><strong>Objectives: </strong>The aims of the present investigation was to develop and validate stability-indicating RP-HPLC method for the estimation of Lurasidone hydrochloride (LURA-H) followed by its drug product, LURA-H encapsulated poly-D,L lactic-glycolic acid (PLGA) based in-situ depot forming implant (LURA-H-PLGA-ISI).</p><p><strong>Methods: </strong>The LURA-H-PLGA-ISI formulation was developed by simple mixing method. According to international conference on harmonization guidelines, RP-HPLC method was developed and validated using Waters 2695 and discovery C18, 5μ, 250×4.6 mm ID column. Force degradation studied were performed by various degradation techniques.</p><p><strong>Results: </strong>The chromatographic separations of LURA-H as well as LURA-H-PLGA-ISI with good resolutions have been achieved using the mobile phase 0.1% orthophosphoric acid and acetonitrile (50:50). The linearity in the range of 25-150 μg/mL of developed method. LOD and LOQ limits for LURA-H were found to be 0.07µg/mL and 0.22 µg/mL, respectively. The % RSD was found to be <2% showing the precision of developed method. The accuracy of developed method was demonstrated which is close to 100±2%. Little modifications in the chromatographic conditions indicated robustness of the developed method. Further, solution stability of LURA-H and LURA-H-PLGA-ISI was stable at room temperature. Furthermore, force degradation studies demonstrated LURA-H was unaffected and stable under thermal, photodegradation and neutral (hydrolytic) stress conditions. AGREE and GAPI assessment demonstrated the developed method is environmentally sustainable.</p><p><strong>Conclusion: </strong>The developed method is simple, robust, precise, accurate and sensitive which can be utilized for the regular analysis of LURA-H in quality control laboratories of bulk drug substance and PLGA containing formulations of LURA-H.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ghita Meknassi Salime, Ali Cherif Chefchaouni, Omar El Hamdaoui, Yassir Elalaoui
{"title":"Self-medication of the pediatric population by parents in Morocco: Survey in the Midelt region.","authors":"Ghita Meknassi Salime, Ali Cherif Chefchaouni, Omar El Hamdaoui, Yassir Elalaoui","doi":"10.1016/j.pharma.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.10.009","url":null,"abstract":"<p><strong>Introduction: </strong>Self-medication, the practice of administering medications without a medical prescription, has become a ubiquitous reality in many homes. Although often seen as a practical solution to alleviate minor ailments, it also raises major concerns, particularly when it involves children. Indeed, self-medication among children by their parents is a complex phenomenon, influenced by various social, cultural and economic factors.</p><p><strong>Objectives: </strong>The main objective of our study is to evaluate the prevalence of self-medication of the pediatric population by parents in the Midelt region and to identify its determinants.</p><p><strong>Methods: </strong>a descriptive cross-sectional study was conducted through a questionnaire with 127 parents of children under 12 years old visiting community pharmacies in the region, between May 1 and October 31, 2022.</p><p><strong>Results: </strong>the prevalence of self-medication was 92.9%, the majority of parents resorted to self-medication of their children for benign pathologies; transient fever, minimal pain and nasopharyngitis. This self-medication is done very early, between 6 months and 2 years. 41.5% of parents used age as a criterion to determine the dose, 49.2% exchanged the dose measurement system between two medications, 76.3% used drug combinations for self-medication, antipyretic analgesics and antibiotics are the therapeutic classes most used in self-medication, 42.2% use the syrup or oral suspension form when self-medicating their children and 64% stated that the pharmacist is their source of information relating to medications.</p><p><strong>Conclusions: </strong>This research found widespread use of self-medication among children by their parents, particularly among those with secondary education living in urban area. These findings underline the need to develop a therapeutic education program intended for families, in collaboration with community pharmacists and various health professionals. The aim is to strengthen the safety of children by encouraging more responsible medical practices within homes.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antioxidant Potential and Phytochemical Constituents of a Synergy Based-Combined Extract of Spondias mombin L., Spilanthes filicaulis (Schumach. & Thonn.) C.D.Adams and Piper guineense Thonn.","authors":"Konei Emangbondji Hounsou, Mubo Adeola Sonibare, Taiwo Olayemi Elufioye","doi":"10.1016/j.pharma.2024.10.007","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.10.007","url":null,"abstract":"<p><strong>Objective: </strong>Recent advancements in scientific understanding of free radicals have stimulated progress in medicine. Antioxidants are known to neutralize free radicals by giving up electrons. The current research was carried out to explore the antioxidant capabilities and phytochemical composition of a synergy-based combined extracts of Spondias mombin, Spilanthes filicaulis, and Piper guineense, with the goal to determine the optimal ratio for the most effective antioxidant activity, suitable for herbal product development.</p><p><strong>Material and methods: </strong>Combined extracts H1 and H2 were obtained through aqueous maceration of S. mombin leaves, S. filicaulis plants, and P. guineense fruits. Antioxidant activity of combined extract was evaluated in 2, 2 - diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing power (FRAP) assay. Evaluations included total phenolic and flavonoid content determination. Furthermore, the phytochemical constituents were determined using Gas Chromatography-Mass Spectrometry (GC-MS).</p><p><strong>Results: </strong>The combined-extract H1 exhibited better free radical scavenging ability in DPPH (IC<sub>50</sub> = 72.87 ± 0.63 µg/mL) than H2 (IC<sub>50</sub> = 150.2 ± 1.08 µg/mL). The FRAP assay results revealed its highest reducing power (12.385± 0.002 AAE/mg/g) compared to H2 (11.657±0.002 AAE/mg/g). Additionally, H1 had higher of both total phenolic and flavonoid content. GC-MS profiling revealed 28 compounds within H1 and 17 compounds within H2.</p><p><strong>Conclusion: </strong>This study demonstrated that the combined extract H1 has significant antioxidant potential, with consistently positive results across all conducted assays. It contains a variety of phytochemical constituents, mainly phenolic and flavonoids that could be explored in pharmaceutical industries to develop antioxidant agents.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Evaluation of the economic impact and the patient pathway in the treatment of chronic total occlusion].","authors":"Lucas Delporte, Marie-Caroline Brianceau, Emir Kaïs Rihani, Morgane Masse, Claire Lauerière, Pascal Odou, Cédric Delhaye, Bertrand Décaudin","doi":"10.1016/j.pharma.2024.10.006","DOIUrl":"10.1016/j.pharma.2024.10.006","url":null,"abstract":"<p><strong>Objectives: </strong>Chronic total occlusion (CTO) of coronary arteries is defined as complete absence of antegrade coronary flow without iodine passage, since more than 3 months. Coronary revascularization is a highly resource-intensive angioplasty procedure involving numerous medical devices (MDs). Its consumption and associated costs are not covered by either the medical act classification (CCAM) or the hospitalization fees and additional MD funding. The primary aim of this study is to analyze the financial sustainability of this activity for a public healthcare institution and to assess the budgetary impact of CTO treatment on the most expensive items of expenditure. The secondary aim is to describe the patient's intra-hospital pathway.</p><p><strong>Methods: </strong>CTO revascularization stays are categorized under the code 05K06 \"Vascular Stents without Myocardial Infarction\". Major cost items were identified using national coded expenditure data and compared with those from our cost study. Every CTO intervention from January to November 2021 were retrospectively retrieved. Establishment purchase prices in 2021 were used to determine MD costs. Clinical data were extracted from electronic patient records. Operative data (procedure duration, professionals involved, and MD used) were extracted. Human Resources (HR) costs were integrated into the calculations. A Sankey diagram was created. Data are expressed as mean±standard deviation.</p><p><strong>Results: </strong>In our study, 41 patients underwent 45 interventions. The median was 65 years. Seventy-eight percent of interventions were successful with a median duration of 113minutes. Two hundred and two different MD references were used, with 27% reimbursed additionally and 73% funded within the homogeneous group of stays (HGS). The total cost of MD described in the coded expenditure data is 2142€, of which 721€ is funded within the HGS. In our cohort, it represented averages of 2736€±1393€ and 1710€±926€, respectively. Regarding HR, the total cost described in the coded expenditure data was 442€ compared to 410€±169€ in our cohort. Finally, patient pathway analysis showed an average length of stay (LOS) of 1.8 days. Two pathways were identified depending on admission context: weekday hospitalization or cardiac intensive care.</p><p><strong>Conclusions: </strong>CTO revascularization is a planned intervention with a short LOS and a highly standardized patient pathway. Our study highlights a proliferation of MD references used during CTO revascularization due to innovative industrial developments. The cost differential with coded expenditure data confirms the need for a revision of the procedure and its categorization within an HGS, which is currently non-specific.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Isavuconazole off-label use as an empirical treatment of invasive fungal infections.","authors":"Anne-Lise Bienvenu, Chloe Gasser, Sophie Ducastelle-Lepretre, Nathalie Bleyzac, Vincent Piriou, Isabelle Durieu, Sandrine Roux, Aurélien Millet, Hervé Ghesquières, Gilles Leboucher, Sylvain Goutelle","doi":"10.1016/j.pharma.2024.10.005","DOIUrl":"10.1016/j.pharma.2024.10.005","url":null,"abstract":"<p><p>Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Imran Kazmi, Hemant K S Yadav, Fahad A Al-Abbasi, Muhammad Afzal, Muhammad Shahid Nadeem, Hisham N Altayb, Abhay Raizaday, Md Sadique Hussain, Haider Ali, Faisal Imam, Gaurav Gupta
{"title":"Design of in-situ implant for the brain-targeted drug delivery using cross-linked gellan gum polymer through response surface methodology.","authors":"Imran Kazmi, Hemant K S Yadav, Fahad A Al-Abbasi, Muhammad Afzal, Muhammad Shahid Nadeem, Hisham N Altayb, Abhay Raizaday, Md Sadique Hussain, Haider Ali, Faisal Imam, Gaurav Gupta","doi":"10.1016/j.pharma.2024.10.004","DOIUrl":"10.1016/j.pharma.2024.10.004","url":null,"abstract":"<p><p>The analysis aimed to prepare an in-situ implant (ISFI) formulation holding dimethyl fumarate as (a model drug) using cross-linked gellan gum by homogenization method. Cross-linking of gellan gum was done with L-cysteine to improve its gelation properties. Fourier transform infrared spectroscopy (FTIR) and (DSC) Differential scanning calorimetry were used to test the compatibility of the drug-polymer. The diverse formulations were prepared and tested using Design Expert® ver 8.0.1 software to optimize the experiment technique and employ the response surface. The tissue compatibility of the test verified the existence of non-irritants in the established formulation. All preparations contained the drug content from approximately 97.98 to 99.88%. Viscosities are ideal for injection in the optimized formulation (1,55 percent w/w in water). The optimized formula was monitored, and up to 156hours, it was found to be 95.7%. The result was that ISFI can effectively monitor and control the delivery of several powerful drug products.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development and in vitro-in vivo evaluation of ocular insert containing ketorolac tromethamine and moxifloxacin hydrochloride.","authors":"Krishna Koradia, Arjun Dedakia, Hiral Koradia","doi":"10.1016/j.pharma.2024.10.002","DOIUrl":"10.1016/j.pharma.2024.10.002","url":null,"abstract":"<p><strong>Purpose: </strong>Conjunctivitis is a common eye disorder that causes swelling and inflammation of the conjunctiva. Topical dosage form containing antibiotics and non-steroidal anti-inflammatory drugs are prescribed for the treatment and in order to overcome problems of conventional dosage forms the present study aims to develop an ocular insert containing moxifloxacin HCl and ketorolac tromethamine.</p><p><strong>Methods: </strong>Insert was prepared by a solvent casting method by taking different polymers PVA, PVP K-30, and a combination of both as film-forming polymer, and glycerol as a plasticizer and characterized by various parameters like thickness, folding endurance, pH, swelling index, drug content, mechanical properties, in vitro and in vivo release study.</p><p><strong>Results: </strong>The formulation prepared by a combination of both polymers demonstrated significantly improved properties including % elongation, tensile strength, swelling index, drug content and drug release compared to the formulation made with single polymer. The in vitro release data indicated that the batch R8 exhibited sustain release of drug (85% release in 10 hr) and following the Higuchi model for release kinetics. In vivo, study in rabbit eyes revealed the sustained release of the drug up to 16 hr with a good correlation between in vitro and in vivo release data.</p><p><strong>Conclusion: </strong>From the study, it can be concluded that the developed ocular insert can be a promising formulation for rational therapy of conjunctivitis.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}